Deregulation of sphingolipid metabolism in Alzheimer's disease.
paper
Cited
Public
Unavailable
- Authors
- He, Xingxuan; Huang, Yu; Li, Bin; Gong, Cheng-Xin; Schuchman, Edward H
- Year
- 2010
- Journal
- Neurobiology of aging
- PMID
- 18547682
- DOI
- 10.1016/j.neurobiolaging.2008.05.010
- PMCID
- PMC2829762
Abnormal sphingolipid metabolism has been previously reported in Alzheimer's disease (AD). To extend these findings, several sphingolipids and sphingolipid hydrolases were analyzed in brain samples from AD patients and age-matched normal individuals. We found a pattern of elevated acid sphingomyelinase (ASM) and acid ceramidase (AC) expression in AD, leading to a reduction in sphingomyelin and elevation of ceramide. More sphingosine also was found in the AD brains, although sphingosine-1-phosphate (S1P) levels were reduced. Notably, significant correlations were observed between the brain ASM and S1P levels and the levels of amyloid beta (Abeta) peptide and hyperphosphorylated tau protein. Based on these findings, neuronal cell cultures were treated with Abeta oligomers, which were found to activate ASM, increase ceramide, and induce apoptosis. Pre-treatment of the neurons with purified, recombinant AC prevented the cells from undergoing Abeta-induced apoptosis. We propose that ASM activation is an important pathological event leading to AD, perhaps due to Abeta deposition. The downstream consequences of ASM activation are elevated ceramide, activation of ceramidases, and production of sphingosine. The reduced levels of S1P in the AD brain, together with elevated ceramide, likely contribute to the disease pathogenesis.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Assessing the critical role of ceramide in the pathogenesis of Alzheimer's disease and its clinical significance. | Huang YW et al. | β | 2026 | β |
| Associations of plasma sphingomyelin SM (d18:1/24:0) with Alzheimer's disease pathology and cognition in non-demented adults. | Guo F et al. | β | 2026 | β |
| Bioenergetics and lipid metabolism in Alzheimer's disease: From cell biology to systemic health. | Maioli S et al. | β | 2026 | β |
| Fingolimod normalizes metabolic signatures associated with synaptic plasticity and memory in APP/PS1 model: Sphingosine-1-phosphate receptor a therapeutic target for Alzheimer's. | KaleckΓ½ K et al. | β | 2026 | β |
| Identification of plasma biomarkers in lipid metabolism for accurate prediction of Alzheimer's disease. | Luo X et al. | β | 2026 | β |
| Sphingolipids in Emotional Well-Being. | Kalinichenko LS et al. | β | 2026 | β |
| Targeting Lipid Metabolism in Alzheimer's Disease: Emerging Insights and Future Directions. | Balakrishnan J et al. | β | 2026 | β |
| The physiological and pathological effects of sphingolipid metabolism and signaling in the central nervous system. | Li T et al. | β | 2026 | β |
| The Role of Ceramides in Metabolic and Cardiovascular Diseases. | Gonzalez-Plascencia M et al. | β | 2026 | β |
| Acid Sphingomyelinase and Ceramide Signaling Pathway Mediates Nicotine-Induced NLRP3 Inflammasome Activation and Podocyte Injury. | Rahman MA et al. | β | 2025 | β |
| Alleviation of Neurological Disorders by Targeting Neurodegenerative-Associated Enzymes: Natural and Synthetic Molecules. | Singh AA et al. | β | 2025 | β |
| Altered Composition of Ceramides and Sphingomyelin Distinctly Modulates the Organizational Landscape and Microdomain Dynamics of Neuronal Plasma Membrane: A Computational Microscopy of Alzheimer's Brain. | Peesapati S et al. | β | 2025 | β |
| A novel fluorescein sodium-based screening platform for the identification of sphingoid base-producing <i>Wickerhamomyces ciferrii</i> mutants. | Kang JS et al. | β | 2025 | β |
| An unraveled mystery: What's the role of brain sphingolipids in neurodegenerative and psychiatric disorders. | Bie X et al. | β | 2025 | β |
| Association of escitalopram-induced shifts in gut microbiota and sphingolipid metabolism with depression-like behavior in wistar-kyoto rats. | Duan J et al. | β | 2025 | β |
| Ceramides may Play a Central Role in the Pathogenesis of Alzheimer's Disease: a Review of Evidence and Horizons for Discovery. | Kalkman HO et al. | β | 2025 | β |
| Concussion-Related Cognitive and Lipid Changes in Retired UK Rugby Players Study. | Alanazi N et al. | β | 2025 | β |
| Early plasma ceramide and sphingomyelin levels reflect APOE genotype but not familial Alzheimer's disease gene mutations in female 5xFAD mice, with brain-region specific sphingolipid alterations. | van Kruining D et al. | β | 2025 | β |
| Glial Biologist's Guide to Mass Spectrometry-Based Lipidomics: A Tutorial From Sample Preparation to Data Analysis. | Randolph CE et al. | β | 2025 | β |
| Impact of APOE on cerebrovascular lipid profile in Alzheimer's disease. | Inoue Y et al. | β | 2025 | β |
| Impact of Manganese on Neuronal Function: An Exploratory Multi-Omics Study on Ferroalloy Workers in Brescia, Italy. | Azmoun S et al. | β | 2025 | β |
| Influence of Ibuprofen on glycerophospholipids and sphingolipids in context of AlzheimerΒ΄s Disease. | Radermacher J et al. | β | 2025 | β |
| Lipid metabolism in microglia: Emerging mechanisms and therapeutic opportunities for neurodegenerative diseases (Review). | Sun Y et al. | β | 2025 | β |
| Lipidome disruption in Alzheimer's disease brain: detection, pathological mechanisms, and therapeutic implications. | He S et al. | β | 2025 | β |
| <i>APOE</i> genotype and biological age impact inter-omic associations related to bioenergetics. | Ellis D et al. | β | 2025 | β |
| Machine learning models of Alzheimer's disease spectrum using blood tests. | Falasca NW et al. | β | 2025 | β |
| Metabolomics-driven exploration of sphingosine 1-phosphate mechanisms in refractory epilepsy. | Ben X et al. | β | 2025 | β |
| miR-137: A therapeutic candidate or a key molecular regulator in Alzheimer's disease? | Wasim M et al. | β | 2025 | β |
| Quantitative analysis of targeted lipidomics in the hippocampus of APP/PS1 mice employing the UHPLC-MS/MS method. | Xiao S et al. | β | 2025 | β |
| Stress Accelerates Depressive-Like Behavior through Increase of SPNS2 Expression in Tg2576 Mice. | Yoo SS et al. | β | 2025 | β |
| Structure and elasticity of healthy and Alzheimer's disease cell membranes revealed by molecular dynamics simulations. | Mai TL et al. | β | 2025 | β |
| The enzyme SMPDL3b in podocytes decouples proteinuria from chronic kidney disease progression in experimental Alport Syndrome. | Mitrofanova A et al. | β | 2025 | β |
| The Involvement of Ceramide, Sphingosine-1-Phosphate and Ganglioside GM1 in Regulating Some Nervous System Functions. | Giussani P et al. | β | 2025 | β |
| The novel sphingolipids cP1P and P1P attenuate neuroinflammation and enhance S1PR1/Akt/mTOR signaling to mitigate cognitive decline in an Alzheimer's disease mouse model. | Choe K et al. | β | 2025 | β |
| The palmitoyl-CoA ligase Fum16 is part of a <i>Fusarium verticillioides</i> fumonisin subcluster involved in self-protection. | Gherlone F et al. | β | 2025 | β |
| The role of sphingolipids in heart failure. | Hamouche R et al. | β | 2025 | β |
| A bidirectional link between sulfatide and Alzheimer's disease. | Zimmer VC et al. | β | 2024 | β |
| Accelerated cognitive aging in chronically infected HIV-1 positive individuals despite effective long-term antiretroviral therapy. | Babu H et al. | β | 2024 | β |
| Acid sphingomyelinase as a pathological and therapeutic target in neurological disorders: focus on Alzheimer's disease. | Choi BJ et al. | β | 2024 | β |
| Alzheimer's disease manifests abnormal sphingolipid metabolism. | Uranbileg B et al. | β | 2024 | β |
| A Near-Infrared Fluorogenic Probe for Rapid, Specific, and Ultrasensitive Detection of Sphingosine in Living Cells and In Vivo. | Chen Y et al. | β | 2024 | β |
| Blood-derived mitochondrial DNA copy number is associated with Alzheimer disease, Alzheimer-related biomarkers and serum metabolites. | Tong T et al. | β | 2024 | β |
| Brain areas lipidomics in female transgenic mouse model of Alzheimer's disease. | FerrΓ©-GonzΓ‘lez L et al. | β | 2024 | β |
| Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer's disease. | Eteleeb AM et al. | β | 2024 | β |
| Correlations of Plasma Biomarkers and Imaging Characteristics of Cerebral Small Vessel Disease. | Kong Q et al. | β | 2024 | β |
| Discovery of antitussive material basis and mechanisms in Citri Sarcodactylis Fructus by coupling UHPLC-Q/Orbitrap HRMS combined spectrum-effect relationship and metabolomics analyses. | Li X et al. | β | 2024 | β |
| Exploring the significance of lipids in Alzheimer's disease and the potential of extracellular vesicles. | Su H et al. | β | 2024 | β |
| Frontal Cortex Lipid Alterations During the Onset of Alzheimer's Disease. | Moreno-Rodriguez M et al. | β | 2024 | β |
| FTIR Spectroscopy and Blood-Derived Extracellular Vesicles Duo in Alzheimer's Disease. | Soares Martins T et al. | β | 2024 | β |
| Fueling Alzheimer's Disease: Where Does Immunometabolism Stand? | Correia SC et al. | β | 2024 | β |
| Lipid metabolism and oxidative stress in patients with Alzheimer's disease and amnestic mild cognitive impairment. | Nie Y et al. | β | 2024 | β |
| New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer's disease. | Cao Y et al. | β | 2024 | β |
| Novel insights into brain lipid metabolism in Alzheimer's disease: Oligodendrocytes and white matter abnormalities. | Kawade N et al. | β | 2024 | β |
| Nuclear SphK2/S1P signaling is a key regulator of ApoE production and AΞ² uptake in astrocytes. | Komai M et al. | β | 2024 | β |
| Nutritional roles and therapeutic potentials of dietary sphingomyelin in brain diseases. | Alashmali S | β | 2024 | β |
| Palmitoyl-L-carnitine induces tau phosphorylation and mitochondrial dysfunction in neuronal cells. | Yoon G et al. | β | 2024 | β |
| Pericytes in Alzheimer's disease: Key players and therapeutic targets. | Zhang Y et al. | β | 2024 | β |
| Phospholipidomics in Clinical Trials for Brain Disorders: Advancing our Understanding and Therapeutic Potentials. | Hachem M et al. | β | 2024 | β |
| Plasma lipidomic signatures of dementia with Lewy bodies revealed by machine learning, and compared to alzheimer's disease. | Shen H et al. | β | 2024 | β |
| Potential therapeutic and diagnostic approaches of exosomes in multiple sclerosis pathophysiology. | Hasaniani N et al. | β | 2024 | β |
| Protective effect of trehalose sugar on amyloid-membrane interactions using BLM electrophysiology. | Xu Y et al. | β | 2024 | β |
| Protein restriction slows the development and progression of pathology in a mouse model of Alzheimer's disease. | Babygirija R et al. | β | 2024 | β |
| Quercetin reshapes gut microbiota homeostasis and modulates brain metabolic profile to regulate depression-like behaviors induced by CUMS in rats. | Li B et al. | β | 2024 | β |
| Sphingosine-1-phosphate Decreases Erythrocyte Dysfunction Induced by Ξ²-Amyloid. | Misiti F et al. | β | 2024 | β |
| Sphingosine 1-phosphate receptor subtype 1 (S1P<sub>1</sub>) activity in the course of Alzheimer's disease. | MartΓnez-Gardeazabal J et al. | β | 2024 | β |
| The function of sphingolipids in different pathogenesis of Alzheimer's disease: A comprehensive review. | Wang X et al. | β | 2024 | β |
| Towards a Unitary Hypothesis of Alzheimer's Disease Pathogenesis. | Area-Gomez E et al. | β | 2024 | β |
| Acid sphingomyelinase (ASM) and COVID-19: A review of the potential use of ASM inhibitors against SARS-CoV-2. | Pauletto PJT et al. | β | 2023 | β |
| Alzheimer's disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy? | Melchiorri D et al. | β | 2023 | β |
| Alzheimer's Disease in Diabetic Patients: A Lipidomic Prospect. | Makki BE et al. | β | 2023 | β |
| Chronic inflammation, neuroglial dysfunction, and plasmalogen deficiency as a new pathobiological hypothesis addressing the overlap between post-COVID-19 symptoms and myalgic encephalomyelitis/chronic fatigue syndrome. | Chaves-Filho AM et al. | β | 2023 | β |
| Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data. | Jo T et al. | β | 2023 | β |
| Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer's disease. | Jung Y et al. | β | 2023 | β |
| GABAergic signaling abnormalities in a novel CLU mutation Alzheimer's disease mouse model. | Chen C et al. | β | 2023 | β |
| Ganglioside GM1 and the Central Nervous System. | Guo Z | β | 2023 | β |
| Glial Sphingosine-Mediated Epigenetic Regulation Stabilizes Synaptic Function in <i>Drosophila</i> Models of Alzheimer's Disease. | Yin P et al. | β | 2023 | β |
| Inhibition of acid sphingomyelinase reduces reactive astrocyte secretion of mitotoxic extracellular vesicles and improves Alzheimer's disease pathology in the 5xFAD mouse. | Crivelli SM et al. | β | 2023 | β |
| Integrated transcriptomic and metabolomic investigation of the genes and metabolites involved in swine follicular cyst formation. | Dai J et al. | β | 2023 | β |
| <i>SGMS2</i> in primary osteoporosis with facial nerve palsy. | PihlstrΓΆm S et al. | β | 2023 | β |
| Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise. | Yin F | β | 2023 | β |
| Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease. | Shi L et al. | β | 2023 | β |
| Neuronal deletion of nSMase2 reduces the production of AΞ² and directly protects neurons. | Tohumeken S et al. | β | 2023 | β |
| Novel Isolation Method Reveals Sex-Specific Composition and Neurotoxicity of Small Extracellular Vesicles in a Mouse Model of Alzheimer's Disease. | Elsherbini A et al. | β | 2023 | β |
| Nutrition in Alzheimer's disease: a review of an underappreciated pathophysiological mechanism. | Jiang J et al. | β | 2023 | β |
| Role of de novo lipogenesis in inflammation and insulin resistance in Alzheimer's disease. | Khan MA et al. | β | 2023 | β |
| Serum lipidomics reveal the mechanism of memory disorder improvement by Qifu decoction. | Deng F et al. | β | 2023 | β |
| Sphingolipid metabolism in brain insulin resistance and neurological diseases. | Mei M et al. | β | 2023 | β |
| Sphingosine 1-phosphate attenuates neuronal dysfunction induced by amyloid-Ξ² oligomers through endocytic internalization of NMDA receptors. | Bigi A et al. | β | 2023 | β |
| Status of Metabolomic Measurement for Insights in Alzheimer's Disease Progression-What Is Missing? | Yin C et al. | β | 2023 | β |
| The relationship among amyloid-Ξ² deposition, sphingomyelin level, and the expression and function of P-glycoprotein in Alzheimer's disease pathological process. | Xing ZK et al. | β | 2023 | β |
| Alteration of plasma metabolic profile and physical performance combined with metabolites is more sensitive to early screening for mild cognitive impairment. | Zhao Y et al. | β | 2022 | β |
| Altered expression of glycobiology-related genes in Parkinson's disease brain. | Schneider JS et al. | β | 2022 | β |
| Arachidonic Acid Cascade and Eicosanoid Production Are Elevated While LTC4 Synthase Modulates the Lipidomics Profile in the Brain of the HIVgp120-Transgenic Mouse Model of NeuroHIV. | Yuan NY et al. | β | 2022 | β |
| A review on neuropharmacological role of erucic acid: an omega-9 fatty acid from edible oils. | Kumar JBS et al. | β | 2022 | β |
| Association Between Plasma Apolipoprotein M With Alzheimer's Disease: A Cross-Sectional Pilot Study From China. | Xin JY et al. | β | 2022 | β |
| Association of Lipidomics Signatures in Blood with Clinical Progression in Preclinical and Prodromal Alzheimer's Disease. | Sakr F et al. | β | 2022 | β |
| ATP-binding cassette protein ABCA7 deficiency impairs sphingomyelin synthesis, cognitive discrimination, and synaptic plasticity in the entorhinal cortex. | Iqbal J et al. | β | 2022 | β |
| AΞ²-Induced Alterations in Membrane Lipids Occur before Synaptic Loss Appears. | Van Bulck M et al. | β | 2022 | β |
| Brain lipidomics: From functional landscape to clinical significance. | Yoon JH et al. | β | 2022 | β |
| Ceramide and Sphingosine-1-Phosphate in Neurodegenerative Disorders and Their Potential Involvement in Therapy. | Tringali C et al. | β | 2022 | β |
| Ceramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer's Disease and Other Neurodegenerative Diseases. | Custodia A et al. | β | 2022 | β |
| Comprehensive metabolomics and lipidomics profiling uncovering neuroprotective effects of <i>Ginkgo biloba</i> L. leaf extract on Alzheimer's disease. | Liu LW et al. | β | 2022 | β |
| Dendrimer-Conjugated nSMase2 Inhibitor Reduces Tau Propagation in Mice. | Tallon C et al. | β | 2022 | β |
| DNA methylation signatures in Blood DNA of Hutchinson-Gilford Progeria syndrome. | Bejaoui Y et al. | β | 2022 | β |
| FTY720 decreases ceramides levels in the brain and prevents memory impairments in a mouse model of familial Alzheimer's disease expressing APOE4. | Crivelli SM et al. | β | 2022 | β |
| Involvement of Huanglian Jiedu Decoction on Microglia with Abnormal Sphingolipid Metabolism in Alzheimer's Disease. | Qi YY et al. | β | 2022 | β |
| Lipidomics of Bioactive Lipids in Alzheimer's and Parkinson's Diseases: Where Are We? | ChiurchiΓΉ V et al. | β | 2022 | β |
| Methylxanthines Induce a Change in the AD/Neurodegeneration-Linked Lipid Profile in Neuroblastoma Cells. | Janitschke D et al. | β | 2022 | β |
| Modulations of bioactive lipids and their receptors in postmortem Alzheimer's disease brains. | Kurano M et al. | β | 2022 | β |
| Protective effects of Liensinine, Isoliensinine, and Neferine on PC12 cells injured by amyloid-Ξ². | Meng XL et al. | β | 2022 | β |
| Reversal of Lipid Metabolism Dysregulation by Selenium and Folic Acid Co-Supplementation to Mitigate Pathology in Alzheimer's Disease. | Zhang ZH et al. | β | 2022 | β |
| Sex Differences in the Metabolome of Alzheimer's Disease Progression. | Zarzar TG et al. | β | 2022 | β |
| Sphingolipid control of cognitive functions in health and disease. | Kalinichenko LS et al. | β | 2022 | β |
| Sphingolipid Metabolism as a New Predictive Target Correlated with Aging and AD: A Transcriptomic Analysis. | D'Angiolini S et al. | β | 2022 | β |
| Sphingomyelins and ceramides: possible biomarkers for dementia? | Loft LMI et al. | β | 2022 | β |
| Vitamin B12 Attenuates Changes in Phospholipid Levels Related to Oxidative Stress in SH-SY5Y Cells. | Theiss EL et al. | β | 2022 | β |
| Acid Ceramidase Protects Against Hepatic Ischemia/Reperfusion Injury by Modulating Sphingolipid Metabolism and Reducing Inflammation and Oxidative Stress. | Jiang Y et al. | β | 2021 | β |
| A Comprehensive Review: Sphingolipid Metabolism and Implications of Disruption in Sphingolipid Homeostasis. | Quinville BM et al. | β | 2021 | β |
| Allele-specific expression and high-throughput reporter assay reveal functional genetic variants associated with alcohol use disorders. | Rao X et al. | β | 2021 | β |
| Alpha-mangostin improves endothelial dysfunction in db/db mice through inhibition of aSMase/ceramide pathway. | Jiang M et al. | β | 2021 | β |
| Anti-depressant effect of Zhi-zi-chi decoction on CUMS mice and elucidation of its signaling pathway. | Chai C et al. | β | 2021 | β |
| Association of Plasma Phospholipids with Age-Related Cognitive Impairment: Results from a Cross-Sectional Study. | Liu TT et al. | β | 2021 | β |
| Bone marrow mesenchymal stem cells-derived exosomes reduce AΞ² deposition and improve cognitive function recovery in mice with Alzheimer's disease by activating sphingosine kinase/sphingosine-1-phosphate signaling pathway. | Wang X et al. | β | 2021 | β |
| Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimer's Disease and Inflammation at the Pre- and Early Stages of Dementia. | Teitsdottir UD et al. | β | 2021 | β |
| Cerebrospinal fluid lipidomics for biomarkers of Alzheimer's disease. | Byeon SK et al. | β | 2021 | β |
| CERT<sub>L</sub> reduces C16 ceramide, amyloid-Ξ² levels, and inflammation in a model of Alzheimer's disease. | Crivelli SM et al. | β | 2021 | β |
| Characterization of brain-derived extracellular vesicle lipids in Alzheimer's disease. | Su H et al. | β | 2021 | β |
| Comprehensive serum metabolic and proteomic characterization on cognitive dysfunction in Parkinson's disease. | Zhang N et al. | β | 2021 | β |
| Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia. | Lee JY et al. | β | 2021 | β |
| Diets with Higher Ο-6/Ο-3 Ratios Show Differences in Ceramides and Fatty Acid Levels Accompanied by Increased Amyloid-Beta in the Brains of Male APP/PS1 Transgenic Mice. | OrdΓ³Γ±ez-GutiΓ©rrez L et al. | β | 2021 | β |
| Enhanced Over-Representation Analysis for the Differential Regulation of <i>Birc5a</i> and <i>HIF2</i>Ξ±-Knockdown Approaches. | Liu CC et al. | β | 2021 | β |
| High-density lipoprotein-related cholesterol metabolism in Alzheimer's disease. | Pedrini S et al. | β | 2021 | β |
| Lipid Profiling of Alzheimer's Disease Brain Highlights Enrichment in Glycerol(phospho)lipid, and Sphingolipid Metabolism. | Akyol S et al. | β | 2021 | β |
| Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids. | Torres M et al. | β | 2021 | β |
| Mitochondria-associated endoplasmic reticulum membranes: At the crossroad between familiar and sporadic Alzheimer's disease. | Wang K et al. | β | 2021 | β |
| Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer's disease. | Yu W et al. | β | 2021 | β |
| New candidate blood biomarkers potentially associated with white matter hyperintensities progression. | JimΓ©nez-Balado J et al. | β | 2021 | β |
| Plasma Sphingomyelins in Late-Onset Alzheimer's Disease. | Fote G et al. | β | 2021 | β |
| Preclinical and Clinical Evidence for the Involvement of Sphingosine 1-Phosphate Signaling in the Pathophysiology of Vascular Cognitive Impairment. | Chua XY et al. | β | 2021 | β |
| Recent Insights into the Interplay of Alpha-Synuclein and Sphingolipid Signaling in Parkinson's Disease. | Motyl JA et al. | β | 2021 | β |
| Shotgun lipidomics of liver and brain tissue of Alzheimer's disease model mice treated with acitretin. | Lauer AA et al. | β | 2021 | β |
| Synapses, Microglia, and Lipids in Alzheimer's Disease. | Paasila PJ et al. | β | 2021 | β |
| Acid Sphingomyelinase Inhibition Mitigates Histopathological and Behavioral Changes in a Murine Model of Traumatic Brain Injury. | Niziolek GM et al. | β | 2020 | β |
| A Small Molecule Fluorogenic Probe for the Detection of Sphingosine in Living Cells. | Rudd AK et al. | β | 2020 | β |
| Ceramide analog [<sup>18</sup>F]F-HPA-12 detects sphingolipid disbalance in the brain of Alzheimer's disease transgenic mice by functioning as a metabolic probe. | Crivelli SM et al. | β | 2020 | β |
| Comprehensive Proteomic Profiling of Urinary Exosomes and Identification of Potential Non-invasive Early Biomarkers of Alzheimer's Disease in 5XFAD Mouse Model. | Song Z et al. | β | 2020 | β |
| Exploring Sphingolipid Implications in Neurodegeneration. | Alessenko AV et al. | β | 2020 | β |
| Impact of sphingosine and acetylsphingosines on the aggregation and toxicity of metal-free and metal-treated amyloid-Ξ². | Yi Y et al. | β | 2020 | β |
| Lipids and Alzheimer's Disease. | Kao YC et al. | β | 2020 | β |
| Lipids as biomarkers of brain disorders. | Hussain G et al. | β | 2020 | β |
| Lysophospholipids and Their G-Coupled Protein Signaling in Alzheimer's Disease: From Physiological Performance to Pathological Impairment. | Hao Y et al. | β | 2020 | β |
| MAM and C99, key players in the pathogenesis of Alzheimer's disease. | Pera M et al. | β | 2020 | β |
| Metabolic Profiling of Cognitive Aging in Midlife. | Huo Z et al. | β | 2020 | β |
| Mitochondria in Alzheimer's disease and their potential role in Alzheimer's proteostasis. | Weidling IW et al. | β | 2020 | β |
| Nicotinamide attenuates the decrease in dendritic spine density in hippocampal primary neurons from 5xFAD mice, an Alzheimer's disease animal model. | Kim H et al. | β | 2020 | β |
| Perspective: The Potential Role of Circulating Lysophosphatidylcholine in Neuroprotection against Alzheimer Disease. | Semba RD | β | 2020 | β |
| Plasma lipidomic biomarker analysis reveals distinct lipid changes in vascular dementia. | Liu Y et al. | β | 2020 | β |
| Self-Protection against the Sphingolipid Biosynthesis Inhibitor Fumonisin B<sub>1</sub> Is Conferred by a <i>FUM</i> Cluster-Encoded Ceramide Synthase. | Janevska S et al. | β | 2020 | β |
| Serum lipidomics study reveals protective effects of Rhodiola crenulata extract on Alzheimer's disease rats. | Sun W et al. | β | 2020 | β |
| Sphingolipid metabolism as a marker of hepatotoxicity in drug-induced liver injury. | Li L et al. | β | 2020 | β |
| Sphingolipids and Inositol Phosphates Regulate the Tau Protein Phosphorylation Status in Humanized Yeast. | Randez-Gil F et al. | β | 2020 | β |
| Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods. | van Kruining D et al. | β | 2020 | β |
| Sphingolipids in Alzheimer's disease, how can we target them? | Crivelli SM et al. | β | 2020 | β |
| Sphingosine 1-phosphate but not Fingolimod protects neurons against excitotoxic cell death by inducing neurotrophic gene expression in astrocytes. | Tran C et al. | β | 2020 | β |
| The role of lipids in autophagy and its implication in neurodegeneration. | Hernandez-Diaz S et al. | β | 2020 | β |
| The Role of Sphingolipids and Specialized Pro-Resolving Mediators in Alzheimer's Disease. | de Wit NM et al. | β | 2020 | β |
| The role of sphingolipids in endoplasmic reticulum stress. | Park WJ et al. | β | 2020 | β |
| The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives. | Lucaciu A et al. | β | 2020 | β |
| The silence of the fats: A MAM's story about Alzheimer. | Agrawal RR et al. | β | 2020 | β |
| 3-Aminophthalhydrazide (Luminol) As a Matrix for Dual-Polarity MALDI MS Imaging. | Li B et al. | β | 2019 | β |
| Acid ceramidase, an emerging target for anti-cancer and anti-angiogenesis. | Cho SM et al. | β | 2019 | β |
| Alzheimer's disease and the autophagic-lysosomal system. | Chung KM et al. | β | 2019 | β |
| Alzheimer's disease and type 2 diabetes mellitus are distinct diseases with potential overlapping metabolic dysfunction upstream of observed cognitive decline. | Chornenkyy Y et al. | β | 2019 | β |
| Beneficial Effects of Fingolimod in Alzheimer's Disease: Molecular Mechanisms and Therapeutic Potential. | Angelopoulou E et al. | β | 2019 | β |
| Comparison of the systemic phospholipid profile in dogs diagnosed with idiopathic inflammatory bowel disease or food-responsive diarrhea before and after treatment. | Kalenyak K et al. | β | 2019 | β |
| Converging and Differential Brain Phospholipid Dysregulation in the Pathogenesis of Repetitive Mild Traumatic Brain Injury and Alzheimer's Disease. | Ojo JO et al. | β | 2019 | β |
| Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease. | Carreras I et al. | β | 2019 | β |
| Dysregulated Choline, Methionine, and Aromatic Amino Acid Metabolism in Patients with Wilson Disease: Exploratory Metabolomic Profiling and Implications for Hepatic and Neurologic Phenotypes. | Mazi TA et al. | β | 2019 | β |
| Exogenous Galactosylceramide as Potential Treatment for CLN3 Disease. | El-Sitt S et al. | β | 2019 | β |
| Global Metabolic Shifts in Age and Alzheimer's Disease Mouse Brains Pivot at NAD+/NADH Redox Sites. | Dong Y et al. | β | 2019 | β |
| Inhibition of acid sphingomyelinase activity ameliorates endothelial dysfunction in <i>db/db</i> mice. | Jiang M et al. | β | 2019 | β |
| Insulin Resistance and Oxidative Stress in the Brain: What's New? | Maciejczyk M et al. | β | 2019 | β |
| Linking Lipid Metabolism to Chromatin Regulation in Aging. | Papsdorf K et al. | β | 2019 | β |
| Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers. | Mesa-Herrera F et al. | β | 2019 | β |
| Lipid Metabolism in Late-Onset Alzheimer's Disease Differs from Patients Presenting with Other Dementia Phenotypes. | Sarrafpour S et al. | β | 2019 | β |
| Lipid transporter Spns2 promotes microglia pro-inflammatory activation in response to amyloid-beta peptide. | Zhong L et al. | β | 2019 | β |
| Metabolomic Study of Hibernating Syrian Hamster Brains: In Search of Neuroprotective Agents. | Gonzalez-Riano C et al. | β | 2019 | β |
| Peripheral adaptive immunity of the triple transgenic mouse model of Alzheimer's disease. | St-Amour I et al. | β | 2019 | β |
| Profiling of Alzheimer's disease related genes in mild to moderate vitamin D hypovitaminosis. | Grimm MOW et al. | β | 2019 | β |
| Role of Ceramidases in Sphingolipid Metabolism and Human Diseases. | Parveen F et al. | β | 2019 | β |
| Sets of Co-regulated Serum Lipids are Associated with Alzheimer Disease Pathophysiology | Barupal DK et al. | β | 2019 | β |
| Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology. | Barupal DK et al. | β | 2019 | β |
| SMPDL3b modulates insulin receptor signaling in diabetic kidney disease. | Mitrofanova A et al. | β | 2019 | β |
| Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases. | Grassi S et al. | β | 2019 | β |
| Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease. | Lei M et al. | β | 2019 | β |
| Temporal Effects of Neuron-specific beta-secretase 1 (BACE1) Knock-in on the Mouse Brain Metabolome: Implications for Alzheimer's Disease. | Pan X et al. | β | 2019 | β |
| The Cross-Talk Between Sphingolipids and Insulin-Like Growth Factor Signaling: Significance for Aging and Neurodegeneration. | JΔΕko H et al. | β | 2019 | β |
| The Lipid Status in Patients with Ulcerative Colitis: Sphingolipids are Disease-Dependent Regulated. | Bazarganipour S et al. | β | 2019 | β |
| The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer's Disease and Other Neurodegenerative Disorders. | Czubowicz K et al. | β | 2019 | β |
| The role of mitochondrial defects and oxidative stress in Alzheimer's disease. | Islam BU et al. | β | 2019 | β |
| Age-Dependent Changes to Sphingolipid Balance in the Human Hippocampus are Gender-Specific and May Sensitize to Neurodegeneration. | Couttas TA et al. | β | 2018 | β |
| A UPLC-TOF/MS-based metabolomics study of rattan stems of Schisandra chinensis effects on Alzheimer's disease rats model. | Yang BY et al. | β | 2018 | β |
| Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. | Varma VR et al. | β | 2018 | β |
| Ceramide and Ischemia/Reperfusion Injury. | He X et al. | β | 2018 | β |
| Ceramide and Its Related Neurochemical Networks as Targets for Some Brain Disorder Therapies. | Brodowicz J et al. | β | 2018 | β |
| Deletion of Specific Sphingolipids in Distinct Neurons Improves Spatial Memory in a Mouse Model of Alzheimer's Disease. | Herzer S et al. | β | 2018 | β |
| Early Candidate Urine Biomarkers for Detecting Alzheimer's Disease Before Amyloid-Ξ² Plaque Deposition in an APP (swe)/PSEN1dE9 Transgenic Mouse Model. | Zhang F et al. | β | 2018 | β |
| Embedded in the Membrane: How Lipids Confer Activity and Specificity to Intramembrane Proteases. | Paschkowsky S et al. | β | 2018 | β |
| Endosomal-Lysosomal Cholesterol Sequestration by U18666A Differentially Regulates Amyloid Precursor Protein (APP) Metabolism in Normal and APP-Overexpressing Cells. | Chung J et al. | β | 2018 | β |
| Enhanced release of acid sphingomyelinase-enriched exosomes generates a lipidomics signature in CSF of Multiple Sclerosis patients. | Pieragostino D et al. | β | 2018 | β |
| Modulation of sphingosine 1-phosphate (S1P) attenuates spatial learning and memory impairments in the valproic acid rat model of autism. | Wu H et al. | β | 2018 | β |
| Neuronal sphingosine kinase 2 subcellular localization is altered in Alzheimer's disease brain. | Dominguez G et al. | β | 2018 | β |
| Ovarian Function Modulates the Effects of Long-Chain Polyunsaturated Fatty Acids on the Mouse Cerebral Cortex. | Herrera JL et al. | β | 2018 | β |
| Particular CSF sphingolipid patterns identify iNPH and AD patients. | Torretta E et al. | β | 2018 | β |
| Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase. | Motyl J et al. | β | 2018 | β |
| Proteomics and lipidomics in the human brain. | Ferrer I | β | 2018 | β |
| PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy. | Haddadi N et al. | β | 2018 | β |
| Quantitative Systems Pharmacology Model for Alzheimer Disease Indicates Targeting Sphingolipid Dysregulation as Potential Treatment Option. | Clausznitzer D et al. | β | 2018 | β |
| Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimer's Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry. | Kaya I et al. | β | 2018 | β |
| Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders. | Di Pardo A et al. | β | 2018 | β |
| Sphingolipidomic Profiling of Rat Serum by UPLC-Q-TOF-MS: Application to Rheumatoid Arthritis Study. | Qu F et al. | β | 2018 | β |
| Sphingolipids in neurodegeneration (with focus on ceramide and S1P). | Wang G et al. | β | 2018 | β |
| Sphingosine kinase 1/sphingosine-1-phosphate receptors dependent signalling in neurodegenerative diseases. The promising target for neuroprotection in Parkinson's disease. | Motyl J et al. | β | 2018 | β |
| The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials. | Miya Shaik M et al. | β | 2018 | β |
| Activation of the NLRP3 inflammasome in microglia: the role of ceramide. | Scheiblich H et al. | β | 2017 | β |
| Alterations of specific lipid groups in serum of obese humans: a review. | Mika A et al. | β | 2017 | β |
| Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease. | Tong M et al. | β | 2017 | β |
| A novel Alzheimer's disease drug candidate targeting inflammation and fatty acid metabolism. | Daugherty D et al. | β | 2017 | β |
| APP Function and Lipids: A Bidirectional Link. | Grimm MO et al. | β | 2017 | β |
| Changes in lipid membranes may trigger amyloid toxicity in Alzheimer's disease. | Drolle E et al. | β | 2017 | β |
| Crosstalk between sphingolipids and vitamin D3: potential role in the nervous system. | Garcia-Gil M et al. | β | 2017 | β |
| Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease. | Di Pardo A et al. | β | 2017 | β |
| Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer's Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry. | Kaya I et al. | β | 2017 | β |
| Discovery and Confirmation of Diagnostic Serum Lipid Biomarkers for Alzheimer's Disease Using Direct Infusion Mass Spectrometry. | Anand S et al. | β | 2017 | β |
| Dysregulation of lipids in Alzheimer's disease and their role as potential biomarkers. | Wong MW et al. | β | 2017 | β |
| Ganglioside and related-sphingolipid profiles are altered in a cellular model of Alzheimer's disease. | Noel A et al. | β | 2017 | β |
| Imaging mass spectrometry (IMS) of cortical lipids from preclinical to severe stages of Alzheimer's disease. | GΓ³nzalez de San RomΓ‘n E et al. | β | 2017 | β |
| Implication of sphingosine-1-phosphate signaling in diseases: molecular mechanism and therapeutic strategies. | Arish M et al. | β | 2017 | β |
| Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease. | Pera M et al. | β | 2017 | β |
| Loss of Sphingosine Kinase Alters Life History Traits and Locomotor Function in <i>Caenorhabditis elegans</i>. | Chan JP et al. | β | 2017 | β |
| Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget. | Hatoum D et al. | β | 2017 | β |
| Metabolomic-guided discovery of Alzheimer's disease biomarkers from body fluid. | Enche Ady CNA et al. | β | 2017 | β |
| Neuronal Cholesterol Accumulation Induced by Cyp46a1 Down-Regulation in Mouse Hippocampus Disrupts Brain Lipid Homeostasis. | Ayciriex S et al. | β | 2017 | β |
| Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention. | Grimm MOW et al. | β | 2017 | β |
| Pleiotropic Effect of Human ApoE4 on Cerebral Ceramide and Saturated Fatty Acid Levels. | den Hoedt S et al. | β | 2017 | β |
| Sepsis-Associated Encephalopathy: The Blood-Brain Barrier and the Sphingolipid Rheostat. | Kuperberg SJ et al. | β | 2017 | β |
| Sphingolipids: membrane microdomains in brain development, function and neurological diseases. | Olsen ASB et al. | β | 2017 | β |
| Sphingomimetic multiple sclerosis drug FTY720 activates vesicular synaptobrevin and augments neuroendocrine secretion. | Darios FD et al. | β | 2017 | β |
| Synthesis, Radiosynthesis, and Preliminary in vitro and in vivo Evaluation of the Fluorinated Ceramide Trafficking Inhibitor (HPA-12) for Brain Applications. | Crivelli SM et al. | β | 2017 | β |
| Targeted Metabolomic Analysis of Soluble Lysates from Platelets of Patients with Mild Cognitive Impairment and Alzheimer's Disease Compared to Healthy Controls: Is PC aeC40:4 a Promising Diagnostic Tool? | Oberacher H et al. | β | 2017 | β |
| The application of lipidomics to biomarker research and pathomechanisms in Alzheimer's disease. | Wong MW et al. | β | 2017 | β |
| Vitamin D<sub>3</sub> protects against AΞ² peptide cytotoxicity in differentiated human neuroblastoma SH- SY5Y cells: A role for S1P1/p38MAPK/ATF4 axis. | Pierucci F et al. | β | 2017 | β |
| Ξ²-Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View. | Penke B et al. | β | 2017 | β |
| Acid Sphingomyelinase Mediates Oxidized-LDL Induced Apoptosis in Macrophage via Endoplasmic Reticulum Stress. | Zhao M et al. | β | 2016 | β |
| A New Method and Mass Spectrometer Design for TOF-SIMS Parallel Imaging MS/MS. | Fisher GL et al. | β | 2016 | β |
| A Signaling Lipid Associated with Alzheimer's Disease Promotes Mitochondrial Dysfunction. | Kennedy MA et al. | β | 2016 | β |
| Cigarette Smoke-Induced Alterations in Frontal White Matter Lipid Profiles Demonstrated by MALDI-Imaging Mass Spectrometry: Relevance to Alzheimer's Disease. | Nunez K et al. | β | 2016 | β |
| Environmental control of microRNAs in the nervous system: Implications in plasticity and behavior. | Codocedo JF et al. | β | 2016 | β |
| Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations. | Ayzenberg I et al. | β | 2016 | β |
| Genome-wide DNA methylation profiling in the superior temporal gyrus reveals epigenetic signatures associated with Alzheimer's disease. | Watson CT et al. | β | 2016 | β |
| Hippocampal lipid differences in Alzheimer's disease: a human brain study using matrix-assisted laser desorption/ionization-imaging mass spectrometry. | Mendis LH et al. | β | 2016 | β |
| MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease. | Yoon H et al. | β | 2016 | β |
| Network Analysis of a Comprehensive Knowledge Repository Reveals a Dual Role for Ceramide in Alzheimer's Disease. | Mizuno S et al. | β | 2016 | β |
| Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse. | Dinkins MB et al. | β | 2016 | β |
| Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System. | Yagami T et al. | β | 2016 | β |
| Peripheral sphingolipids are associated with variation in white matter microstructure in older adults. | Gonzalez CE et al. | β | 2016 | β |
| Regulation of sphingomyelin metabolism. | Bienias K et al. | β | 2016 | β |
| The lipidome associated with the Ξ³-secretase complex is required for its integrity and activity. | Ayciriex S et al. | β | 2016 | β |
| (1)H NMR brain metabonomics of scrapie exposed sheep. | Scano P et al. | β | 2015 | β |
| Alkaline Ceramidase 3 Deficiency Results in Purkinje Cell Degeneration and Cerebellar Ataxia Due to Dyshomeostasis of Sphingolipids in the Brain. | Wang K et al. | β | 2015 | β |
| Application of a novel metabolomic approach based on atmospheric pressure photoionization mass spectrometry using flow injection analysis for the study of Alzheimer's disease. | GonzΓ‘lez-DomΓnguez R et al. | β | 2015 | β |
| ASM in Alzheimer's disease. | Lee JK et al. | β | 2015 | β |
| Ceramides in Alzheimer's Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and AΞ² Accumulation. | JazvinΕ‘Δak Jembrek M et al. | β | 2015 | β |
| Computational modeling of sphingolipid metabolism. | Wronowska W et al. | β | 2015 | β |
| Defective Self-Renewal and Differentiation of GBA-Deficient Neural Stem Cells Can Be Restored By Macrophage Colony-Stimulating Factor. | Lee H et al. | β | 2015 | β |
| Diet, nutrients and metabolism: cogs in the wheel driving Alzheimer's disease pathology? | Creegan R et al. | β | 2015 | β |
| GluN2B-containing NMDA receptors are upregulated in plasma membranes by the sphingosine-1-phosphate analog FTY720P. | Attiori Essis S et al. | β | 2015 | β |
| Lipidomics in drug development. | Dehairs J et al. | β | 2015 | β |
| Lipidomics of human brain aging and Alzheimer's disease pathology. | NaudΓ A et al. | β | 2015 | β |
| Metabolic Modifications in Human Biofluids Suggest the Involvement of Sphingolipid, Antioxidant, and Glutamate Metabolism in Alzheimer's Disease Pathogenesis. | Ellis B et al. | β | 2015 | β |
| Metabolomic investigation of systemic manifestations associated with Alzheimer's disease in the APP/PS1 transgenic mouse model. | GonzΓ‘lez-DomΓnguez R et al. | β | 2015 | β |
| Protective effects of ginsenosides Rg1 and Rb1 on an Alzheimer's disease mouse model: a metabolomics study. | Li N et al. | β | 2015 | β |
| Rapid evaluation of 25 key sphingolipids and phosphosphingolipids in human plasma by LC-MS/MS. | Basit A et al. | β | 2015 | β |
| Regulation of TRPML1 function. | Waller-Evans H et al. | β | 2015 | β |
| Role of sphingomyelinases in neurological disorders. | Ong WY et al. | β | 2015 | β |
| Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's disease. | Fonteh AN et al. | β | 2015 | β |
| Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-Ξ²42, tau, and phospho-tau-181 levels. | Koal T et al. | β | 2015 | β |
| Sphingosin-1-phosphate Receptor 1: a Potential Target to Inhibit Neuroinflammation and Restore the Sphingosin-1-phosphate Metabolism. | Kolahdooz Z et al. | β | 2015 | β |
| Sphingosine-1-phosphate and its effect on glucose deprivation/glucose reload stress: from gene expression to neuronal survival. | Czubowicz K et al. | β | 2015 | β |
| The ATP-Binding Cassette Transporter-2 (ABCA2) Overexpression Modulates Sphingosine Levels and Transcription of the Amyloid Precursor Protein (APP) Gene. | Davis W | β | 2015 | β |
| The emerging role of acid sphingomyelinase in autophagy. | Perrotta C et al. | β | 2015 | β |
| The Molecular Mechanism of Amyloid Ξ²42 Peptide Toxicity: The Role of Sphingosine Kinase-1 and Mitochondrial Sirtuins. | CieΕlik M et al. | β | 2015 | β |
| What can lipidomics tell us about the pathogenesis of Alzheimer disease? | Xiang Y et al. | β | 2015 | β |
| White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease. | Klosinski LP et al. | β | 2015 | β |
| Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimer's disease. | Lee JK et al. | β | 2014 | β |
| Altered levels of serum sphingomyelin and ceramide containing distinct acyl chains in young obese adults. | Hanamatsu H et al. | β | 2014 | β |
| Ceramide in the molecular mechanisms of neuronal cell death. The role of sphingosine-1-phosphate. | Czubowicz K et al. | β | 2014 | β |
| Ceramides and sphingomyelinases in senile plaques. | Panchal M et al. | β | 2014 | β |
| Cerebrospinal fluid sphingolipids, Ξ²-amyloid, and tau in adults at risk for Alzheimer's disease. | Mielke MM et al. | β | 2014 | β |
| Combating neurodegenerative disease with chemical probes and model systems. | Narayan P et al. | β | 2014 | β |
| Fingolimod for the treatment of neurological diseases-state of play and future perspectives. | Brunkhorst R et al. | β | 2014 | β |
| Gene expression profiles of entorhinal cortex in Alzheimer's disease. | Ding B et al. | β | 2014 | β |
| HFE gene variants, iron, and lipids: a novel connection in Alzheimer's disease. | Ali-Rahmani F et al. | β | 2014 | β |
| Improved sphingolipidomic approach based on ultra-high performance liquid chromatography and multiple mass spectrometries with application to cellular neurotoxicity. | Wang JR et al. | β | 2014 | β |
| IPAF inflammasome is involved in interleukin-1Ξ² production from astrocytes, induced by palmitate; implications for Alzheimer's Disease. | Liu L et al. | β | 2014 | β |
| Lipid integration in neurodegeneration: an overview of Alzheimer's disease. | Yadav RS et al. | β | 2014 | β |
| Lipid metabolism in Alzheimer's disease. | Liu Q et al. | β | 2014 | β |
| Lipidomics of Alzheimer's disease. | Touboul D et al. | β | 2014 | β |
| Long-term food restriction prevents aging-associated sphingolipid turnover dysregulation in the brain. | Babenko NA et al. | β | 2014 | β |
| Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. | Couttas TA et al. | β | 2014 | β |
| Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology. | Wood PL | β | 2014 | β |
| Pathological roles of ceramide and its metabolites in metabolic syndrome and Alzheimer's disease. | Yuyama K et al. | β | 2014 | β |
| Prominence of central sphingosine-1-phosphate receptor-1 in attenuating aΞ²-induced injury by fingolimod. | Asle-Rousta M et al. | β | 2014 | β |
| Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease. | Ceccom J et al. | β | 2014 | β |
| Sphingolipids and lysosomal pathologies. | Schulze H et al. | β | 2014 | β |
| Sphingolipids in lung growth and repair. | Tibboel J et al. | β | 2014 | β |
| Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by 1-methyl-4-phenylpyridinium (MPP+) in human dopaminergic neuronal cells. | Pyszko J et al. | β | 2014 | β |
| Sphingosine kinase-1 protects differentiated N2a cells against beta-amyloid25-35-induced neurotoxicity via the mitochondrial pathway. | Yang Y et al. | β | 2014 | β |
| The role of inflammasome in Alzheimer's disease. | Liu L et al. | β | 2014 | β |
| Acid ceramidase maintains the chondrogenic phenotype of expanded primary chondrocytes and improves the chondrogenic differentiation of bone marrow-derived mesenchymal stem cells. | Simonaro CM et al. | β | 2013 | β |
| Activation of sphingosine 1-phosphate receptor-1 by SEW2871 improves cognitive function in Alzheimer's disease model rats. | Asle-Rousta M et al. | β | 2013 | β |
| Ceramide function in the brain: when a slight tilt is enough. | Mencarelli C et al. | β | 2013 | β |
| Characterization of acid sphingomyelinase activity in human cerebrospinal fluid. | MΓΌhle C et al. | β | 2013 | β |
| Cross-talk of membrane lipids and Alzheimer-related proteins. | Walter J et al. | β | 2013 | β |
| Effects of small interfering RNA targeting sphingosine kinase-1 gene on the animal model of Alzheimer's disease. | Zhang Y et al. | β | 2013 | β |
| FTY720/fingolimod, a sphingosine analogue, reduces amyloid-Ξ² production in neurons. | Takasugi N et al. | β | 2013 | β |
| FTY720 (fingolimod) attenuates beta-amyloid peptide (AΞ²42)-induced impairment of spatial learning and memory in rats. | Asle-Rousta M et al. | β | 2013 | β |
| Functional inhibitors of acid sphingomyelinase (FIASMAs). | Kornhuber J et al. | β | 2013 | β |
| Inhibition of serine palmitoyltransferase reduces AΞ² and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease. | Geekiyanage H et al. | β | 2013 | β |
| Lysophospholipids and their receptors in the central nervous system. | Choi JW et al. | β | 2013 | β |
| Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine. | Hemmati F et al. | β | 2013 | β |
| Palmitate-activated astrocytes via serine palmitoyltransferase increase BACE1 in primary neurons by sphingomyelinases. | Liu L et al. | β | 2013 | β |
| Phospholipids and Alzheimer's disease: alterations, mechanisms and potential biomarkers. | Kosicek M et al. | β | 2013 | β |
| Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. | Rembach A et al. | β | 2013 | β |
| Role of ceramide in diabetes mellitus: evidence and mechanisms. | Galadari S et al. | β | 2013 | β |
| Sphingolipid metabolic pathway: an overview of major roles played in human diseases. | Pralhada Rao R et al. | β | 2013 | β |
| The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease. | Grimm MO et al. | β | 2013 | β |
| Vesicle size determines unitary exocytic properties and their sensitivity to sphingosine. | FlaΕ‘ker A et al. | β | 2013 | β |
| Ceramide profiles in the brain of rats with diabetes induced by streptozotocin. | Car H et al. | β | 2012 | β |
| Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease? | Mielke MM et al. | β | 2012 | β |
| Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease. | de la Monte SM et al. | β | 2012 | β |
| Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease. | Kosicek M et al. | β | 2012 | β |
| Functional implications of novel human acid sphingomyelinase splice variants. | Rhein C et al. | β | 2012 | β |
| Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases. | Filippov V et al. | β | 2012 | β |
| Lipidomics of Alzheimer's disease: current status. | Wood PL | β | 2012 | β |
| Localized sphingolipid signaling at presynaptic terminals is regulated by calcium influx and promotes recruitment of priming factors. | Chan JP et al. | β | 2012 | β |
| Metabonomic profiling of TASTPM transgenic Alzheimer's disease mouse model. | Hu ZP et al. | β | 2012 | β |
| Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. | Mielke MM et al. | β | 2012 | β |
| Sphingolipids: critical players in Alzheimer's disease. | van Echten-Deckert G et al. | β | 2012 | β |
| Sphingosine regulates the NLRP3-inflammasome and IL-1Ξ² release from macrophages. | Luheshi NM et al. | β | 2012 | β |
| The role of APP proteolytic processing in lipid metabolism. | Grimm MO et al. | β | 2012 | β |
| The roles of neutral sphingomyelinases in neurological pathologies. | Horres CR et al. | β | 2012 | β |
| Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. | de la Monte SM | β | 2012 | β |
| Vitamin K, an emerging nutrient in brain function. | Ferland G | β | 2012 | β |
| Diet-induced elevations in serum cholesterol are associated with alterations in hippocampal lipid metabolism and increased oxidative stress. | Stranahan AM et al. | β | 2011 | β |
| Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology. | Frisardi V et al. | β | 2011 | β |
| Hyperglycemia magnifies Schwann cell dysfunction and cell death triggered by PA-induced lipotoxicity. | Padilla A et al. | β | 2011 | β |
| Identification of novel functional inhibitors of acid sphingomyelinase. | Kornhuber J et al. | β | 2011 | β |
| Intracellular APP Domain Regulates Serine-Palmitoyl-CoA Transferase Expression and Is Affected in Alzheimer's Disease. | Grimm MO et al. | β | 2011 | β |
| Lifelong low-phylloquinone intake is associated with cognitive impairments in old rats. | CarriΓ© I et al. | β | 2011 | β |
| Linking lipids to Alzheimer's disease: cholesterol and beyond. | Di Paolo G et al. | β | 2011 | β |
| Metabolome in progression to Alzheimer's disease. | OreΕ‘iΔ M et al. | β | 2011 | β |
| MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid Ξ², novel targets in sporadic Alzheimer's disease. | Geekiyanage H et al. | β | 2011 | β |
| Phospholipases A2 and neural membrane dynamics: implications for Alzheimer's disease. | Lee JC et al. | β | 2011 | β |
| Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. | Mielke MM et al. | β | 2011 | β |
| Regulation of phosphatidic Acid metabolism by sphingolipids in the central nervous system. | PasquarΓ© SJ et al. | β | 2011 | β |
| Secondary alterations of sphingolipid metabolism in lysosomal storage diseases. | Prinetti A et al. | β | 2011 | β |
| Sphingosine-1-phosphate links glycosphingolipid metabolism to neurodegeneration via a calpain-mediated mechanism. | Hagen N et al. | β | 2011 | β |
| Sphingosine induces apoptosis in hippocampal neurons and astrocytes by activating caspase-3/-9 via a mitochondrial pathway linked to SDK/14-3-3 protein/Bax/cytochrome c. | Kanno T et al. | β | 2011 | β |
| Sphingosylphosphorylcholine attenuated Ξ²-amyloid production by reducing BACE1 expression and catalysis in PC12 cells. | Yi H et al. | β | 2011 | β |
| The polyunsaturated fatty acids, EPA and DPA exert a protective effect in the hippocampus of the aged rat. | Kelly L et al. | β | 2011 | β |
| 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine ameliorates age-related spatial memory deterioration by preventing neuronal cell death. | Yaguchi T et al. | β | 2010 | β |
| Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets? | Mielke MM et al. | β | 2010 | β |
| Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. | de la Monte SM et al. | β | 2010 | β |
| Ceramide-rich platforms in transmembrane signaling. | Stancevic B et al. | β | 2010 | β |
| Control of metabolism and signaling of simple bioactive sphingolipids: Implications in disease. | Gangoiti P et al. | β | 2010 | β |
| Disturbance in cerebral spinal fluid sphingolipid content is associated with memory impairment in subjects infected with the human immunodeficiency virus. | Mielke MM et al. | β | 2010 | β |
| Mammalian neutral sphingomyelinases: regulation and roles in cell signaling responses. | Wu BX et al. | β | 2010 | β |
| Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseases. | Fantini J et al. | β | 2010 | β |
| Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. | Mielke MM et al. | β | 2010 | β |
| Regulating survival and development in the retina: key roles for simple sphingolipids. | Rotstein NP et al. | β | 2010 | β |
| Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. | Haughey NJ et al. | β | 2010 | β |
| S1P metabolism in cancer and other pathological conditions. | Leong WI et al. | β | 2010 | β |
| Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. | Serra M et al. | β | 2010 | β |
| The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? | Broersen K et al. | β | 2010 | β |
| Lyase to live by: sphingosine phosphate lyase as a therapeutic target. | Kumar A et al. | β | 2009 | β |
| Mechanisms of ceramide-mediated neurodegeneration. | Tong M et al. | β | 2009 | β |
| Sphingosine facilitates SNARE complex assembly and activates synaptic vesicle exocytosis. | Darios F et al. | β | 2009 | β |